A detailed history of Legal & General Group PLC transactions in Pulmonx Corp stock. As of the latest transaction made, Legal & General Group PLC holds 24,784 shares of LUNG stock, worth $157,130. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,784
Previous 24,784 -0.0%
Holding current value
$157,130
Previous $229,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$8.71 - $14.65 $10,129 - $17,037
-1,163 Reduced 4.48%
24,784 $229,000
Q4 2023

Feb 15, 2024

SELL
$7.89 - $13.14 $43,063 - $71,718
-5,458 Reduced 17.38%
25,947 $330,000
Q3 2023

Nov 14, 2023

SELL
$9.88 - $14.0 $2,203 - $3,122
-223 Reduced 0.71%
31,405 $324,000
Q2 2023

Aug 14, 2023

BUY
$10.78 - $13.65 $133,208 - $168,673
12,357 Added 64.12%
31,628 $414,000
Q1 2023

May 15, 2023

BUY
$7.49 - $12.54 $54,624 - $91,454
7,293 Added 60.89%
19,271 $215,000
Q4 2022

Feb 14, 2023

SELL
$4.92 - $17.35 $1,584 - $5,586
-322 Reduced 2.62%
11,978 $100,000
Q3 2022

Nov 14, 2022

SELL
$15.35 - $23.99 $60,310 - $94,256
-3,929 Reduced 24.21%
12,300 $205,000
Q2 2022

Aug 22, 2022

BUY
$14.0 - $27.95 $122,080 - $243,724
8,720 Added 116.13%
16,229 $239,000
Q1 2022

May 16, 2022

BUY
$21.13 - $35.65 $105 - $178
5 Added 0.07%
7,509 $186,000
Q4 2021

Feb 14, 2022

BUY
$29.72 - $45.1 $861 - $1,307
29 Added 0.39%
7,504 $240,000
Q3 2021

Nov 15, 2021

BUY
$35.98 - $44.48 $133,197 - $164,664
3,702 Added 98.12%
7,475 $268,000
Q2 2021

Aug 12, 2021

BUY
$37.61 - $48.0 $86,916 - $110,928
2,311 Added 158.07%
3,773 $166,000
Q1 2021

May 17, 2021

SELL
$44.0 - $67.54 $2,948 - $4,525
-67 Reduced 4.38%
1,462 $67,000
Q4 2020

Feb 12, 2021

BUY
$39.31 - $69.02 $60,104 - $105,531
1,529 New
1,529 $105,000

Others Institutions Holding LUNG

About Pulmonx Corp


  • Ticker LUNG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 37,268,400
  • Market Cap $236M
  • Description
  • Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a ...
More about LUNG
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.